Mersana's lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback